Ziyi Niu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ziyi Niu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ceng Luo
Department of Neurobiology, School of Basic Medicine, Fourth Military Medical University, Xi’an, China
1 shared publication - Futai Wang
Department of Neurobiology, School of Basic Medicine, Fourth Military Medical University, Xi’an 710032, China
1 shared publication - Peiyang Liu
Department of Neurobiology, School of Basic Medicine, Fourth Military Medical University, Xi’an 710032, China
1 shared publication - Rou-Gang Xie
Department of Neurobiology, School of Basic Medicine, Fourth Military Medical University, Xi’an, China
1 shared publication - Wenchao Hu
Department of Neurobiology, School of Basic Medicine, Fourth Military Medical University, Xi’an 710032, China
1 shared publication - Zhicheng Tian
Department of Neurosurgery, Xijing Hospital Fourth Military Medical University Xi'an China
1 shared publication
Latest Publications
- Open Access
- 29 August 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (9) , 921
Peripheral Nerve Injury Induces an Interferon-Responsive State Centered on Satellite Glial Cells in the DRG That Sustains Neuropathic Pain Through STAT1 and CXCL10 Signaling
Background: Peripheral nerve injury drives persistent remodeling of the dorsal root ganglion (DRG) microenvironment, but the cellular states and intercellular signaling mechanisms that sustain neuropathic pain remain poorly understood. Methods: Here, we integrated single-cell transcriptomics with histological, behavioral, and electrophysiological approaches to identify an interferon-responsive state in satellite glial cells (SGCs) of the DRG following spared nerve injury (SNI). Results: This state was distinguished by STAT1-associated interferon-responsive genes’ activation and enhanced chemokine signaling, particularly involving CXCL10 and its receptor CXCR3. These molecular alterations were accompanied by remodeling of intercellular communication among SGCs, sensory neurons, and immune cells. Pharmacological inhibition of STAT1 or blockade of CXCR3 not only reduced sensory-neuron hyperexcitability but also attenuated pain hypersensitivity and improved deficits in hindlimb weight bearing and gait after SNI. Conclusions: Collectively, our findings indicate that interferon-responsive SGCs (IFN SGCs) contribute to the maintenance of neuropathic pain by regulating STAT1-dependent chemokine signaling in the DRG. Targeting this signaling pathway may provide a therapeutic strategy for persistent neuropathic pain.
- 29 August 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (9) , 921
Open AccessPeripheral Nerve Injury Induces an Interferon-Responsive State Centered on Satellite Glial Cells in the DRG That Sustains Neuropathic Pain Through STAT1 and CXCL10 Signaling
Background: Peripheral nerve injury drives persistent remodeling of the dorsal root ganglion (DRG) microenvironment, but the cellular states and intercellular signaling mechanisms that sustain neuropathic pain remain poorly understood. Methods: Here, we integrated single-cell transcriptomics with histological, behavioral, and electrophysiological approaches to identify an interferon-responsive state in satellite glial cells (SGCs) of the DRG following spared nerve injury (SNI). Results: This state was distinguished by STAT1-associated interferon-responsive genes’ activation and enhanced chemokine signaling, particularly involving CXCL10 and its receptor CXCR3. These molecular alterations were accompanied by remodeling of intercellular communication among SGCs, sensory neurons, and immune cells. Pharmacological inhibition of STAT1 or blockade of CXCR3 not only reduced sensory-neuron hyperexcitability but also attenuated pain hypersensitivity and improved deficits in hindlimb weight bearing and gait after SNI. Conclusions: Collectively, our findings indicate that interferon-responsive SGCs (IFN SGCs) contribute to the maintenance of neuropathic pain by regulating STAT1-dependent chemokine signaling in the DRG. Targeting this signaling pathway may provide a therapeutic strategy for persistent neuropathic pain.